SEHK:6826Biotechs
Haohai BioTech SEHK 6826 One Off C¥167.7m Loss Tests Bullish Earnings Narratives
Shanghai Haohai Biological Technology (SEHK:6826) has wrapped up FY 2025 with fourth quarter revenue of C¥573.9 million and a basic EPS loss of C¥0.23, while the trailing twelve month basic EPS sits at C¥1.08 on revenue of about C¥2.5 billion. Over recent periods the company has seen quarterly revenue move between C¥573.9 million and C¥685.9 million, with basic EPS ranging from a loss of C¥0.23 to a profit of C¥0.52. This presents a mixed earnings picture across the year. With a trailing net...